NASDAQ:CBMG Cellular Biomedicine Group (CBMG) Stock Price, News & Analysis → Trump’s “Tax Free” Retirement Strategy (From Gold Safe Exchange) (Ad) Free CBMG Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range N/A50-Day Range$17.67▼$19.7552-Week Range N/AVolume8,375 shsAverage Volume129,776 shsMarket Capitalization$384.69 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Cellular Biomedicine Group alerts: Email Address Ad Gold Safe ExchangeTrump’s “Tax Free” Retirement Strategy Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.Protect your retirement savings from the inevitable devaluation of the dollar… About Cellular Biomedicine Group Stock (NASDAQ:CBMG)Cellular Biomedicine Group, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for cancer and stem cell therapies for degenerative diseases in Greater China. The company develops treatments utilizing proprietary cell based technologies, including immune cell therapy for treating a range of cancer indications comprising technologies in chimeric antigen receptor modified T cells (CAR-T), T-cells with genetically modified, tumor antigen-specific T-cell receptors, and next generation neoantigen-reactive bio-markers based tumor infiltrating lymphocytes; and human adipose-derived mesenchymal progenitor cells for the treatment of joint diseases The company's CAR-T products include CD20 for use in anti-tumor activities; CD22, a surface maker highly expressed in B cell malignancies in hairy cell leukemia; and B-cell maturation antigen therapies for treating refractory multiple myeloma in patients. It also develops NKG2D CAR therapies for use in NK cell signaling; alpha fetoprotein TCR-T therapies for treating hepatocellular carcinoma; tumor infiltrating lymphocyte therapies for treating immunogenic cancers; and knee osteoarthritis therapies, including AlloJoin therapy, which is in a Phase II clinical trial, as well as Re-Join that has completed the Phase IIb clinical trial. In addition, it engages in biopharmaceutical businesses, including research and development, technical support, technical service, and technology transfer activities in biomedical technology field; manufacturing non-food, pharmaceutical polypeptides, and medical devices; and the wholesale of cosmetics, sanitary products, and biological agents. The company has a collaboration agreement with Novartis Pharma AG to manufacture and supply their CAR-T cell therapy Kymriah in China. Cellular Biomedicine Group, Inc. was incorporated in 2001 and is headquartered in New York, New York.Read More Ad Gold Safe ExchangeTrump’s “Tax Free” Retirement Strategy Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.Protect your retirement savings from the inevitable devaluation of the dollar… CBMG Stock News HeadlinesMarch 26, 2024 | tmcnet.comCavli Wireless All Set to Introduce the 5G RedCap CQM220 Cellular IoT Module at Embedded World 2024March 21, 2024 | markets.businessinsider.comIntra-Cellular Promotes Michael To PresidentMarch 28, 2024 | Gold Safe Exchange (Ad)Trump’s “Tax Free” Retirement Strategy Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.March 13, 2024 | msn.comIlluminating Cellular Dynamics Advancements in Visualizing Lipid Membrane Order with Solvatochromic ProbesMarch 11, 2024 | seekingalpha.comIntra-Cellular Therapies Is On FireMarch 6, 2024 | benzinga.comHHLR ADVISORS, LTD.'s Net WorthMarch 1, 2024 | finance.yahoo.comMillicom International Cellular S.A. (NASDAQ:TIGO) Just Reported Full-Year Earnings: Have Analysts Changed Their Mind On The Stock?February 26, 2024 | msn.comMillicom International Cellular S.A. Q4 2023 Earnings PreviewMarch 28, 2024 | Gold Safe Exchange (Ad)Trump’s “Tax Free” Retirement Strategy Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.February 26, 2024 | markets.businessinsider.comIntra-Cellular Therapies: Sustained Growth and Buy Opportunity Amid Caplyta’s ProgressFebruary 24, 2024 | uk.news.yahoo.comAT&T and Other Providers Hit by Widespread Cellular OutagesFebruary 23, 2024 | msn.comConsumer Cellular Cell Phone Plan Review 2024February 22, 2024 | markets.businessinsider.comBuy Rating Affirmed for Intra-Cellular Therapies on Strong Caplyta Sales and Promising Clinical TrialsFebruary 21, 2024 | markets.businessinsider.comIntra-Cellular Therapies earnings preview: what to expectFebruary 20, 2024 | msn.comSarah Michelle Gellar Says There’s ‘No Roadmap’ for Parenting in the Cellular Age [Exclusive]February 20, 2024 | msn.comUnited States Cellular Corporation (NYSE:USM) Q4 2023 Earnings Call TranscriptFebruary 19, 2024 | msn.comPresident Droupadi Murmu visits Cellular Jail in AndamanFebruary 16, 2024 | marketwatch.comTDS Posts Lower 4Q Revenue, Dragged Down by US Cellular SoftnessFebruary 15, 2024 | benzinga.comEarnings Preview For United States CellularFebruary 15, 2024 | markets.businessinsider.comUnited States Cellular earnings preview: what to expectFebruary 6, 2024 | msn.comIs US Cellular Down? Users Complain of Signal Issues Amid Power Outage Reports in Waterloo and Cedar FallsJanuary 26, 2024 | msn.comUS Cellular, Telephone and Data gain as T-Mobile US says looking at sales processJanuary 25, 2024 | finance.yahoo.comBe Biopharma to Present at Keystone Symposia on Emerging Cellular TherapiesJanuary 24, 2024 | markets.businessinsider.comPatriot Mobile Receives “Ladies Choice” Award for “Best Cellular Service”January 22, 2024 | finanznachrichten.deAmerican Society for Transplantation and Cellular Therapy: ASTCT, AACI, and ACCC Launch RECUR Initiative to Enhance Patient Access to CAR T TherapyJanuary 18, 2024 | msn.comBest Cellular Security Systems in 2024January 15, 2024 | finance.yahoo.comGlobal Private 5G/4G Cellular Networks for Utilities Industry Report 2023-2030: Smart Grid Communications Drive Adoption of Private Cellular NetworksSee More Headlines Receive CBMG Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cellular Biomedicine Group and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/09/2020Today3/28/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological Products, Except Diagnostic Sub-IndustryN/A Current SymbolNASDAQ:CBMG CUSIPN/A CIK1378624 Webwww.cellbiomedgroup.com Phone347-905-5663FaxN/AEmployees217Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-49,980,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-144.80% Return on Assets-61.68% Debt Debt-to-Equity RatioN/A Current Ratio0.47 Quick Ratio0.47 Sales & Book Value Annual Sales$340,000.00 Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value$2.89 per share Price / BookN/AMiscellaneous Outstanding Shares19,478,000Free FloatN/AMarket Cap$384.69 million OptionableOptionable Beta1.35 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesMr. Bizuo Liu (Age 56)CEO, CFO & Exec. Director Comp: $541.33kDr. Yihong Yao (Age 53)Chief Scientific Officer Comp: $364.98kMr. Andrew K. Chan (Age 63)Chief Legal Officer (Gen. Counsel), Sr. VP of Corp. Devel. & Sec. Comp: $475.08kMr. Derrick C. LiHead of Strategy & Investor RelationsMs. Sarah KellyDirector of Corp. CommunicationsDr. Li ZhangChief Production OfficerProf. Zhong Chen KouChief Scientist of ImmunologyDr. Xia Meng Ph.D.BS, Head of Early Diagnosis & InterventionMr. Michael HumphriesHead of Devel. & StrategyMore ExecutivesKey CompetitorsTScan TherapeuticsNASDAQ:TCRXHarpoon TherapeuticsNASDAQ:HARPTenaya TherapeuticsNASDAQ:TNYALexeo TherapeuticsNASDAQ:LXEOProKidneyNASDAQ:PROKView All Competitors CBMG Stock Analysis - Frequently Asked Questions How were Cellular Biomedicine Group's earnings last quarter? Cellular Biomedicine Group, Inc. (NASDAQ:CBMG) posted its quarterly earnings data on Monday, November, 9th. The biotechnology company reported ($0.88) earnings per share for the quarter, missing the consensus estimate of ($0.63) by $0.25. The biotechnology company had revenue of $0.03 million for the quarter. What other stocks do shareholders of Cellular Biomedicine Group own? Based on aggregate information from My MarketBeat watchlists, some companies that other Cellular Biomedicine Group investors own include CRISPR Therapeutics (CRSP), Aduro Biotech (ADRO), Amarin (AMRN), Anavex Life Sciences (AVXL), Adaptimmune Therapeutics (ADAP), Exelixis (EXEL), Fate Therapeutics (FATE), ImmunoGen (IMGN), AT&T (T) and Iovance Biotherapeutics (IOVA). This page (NASDAQ:CBMG) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyBREAKING: New AI Breakthrough Could Change Healthcare ForeverBehind the Markets“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisorySHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceBuy this small stock before coming AI Tidal WaveChaikin Analytics Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cellular Biomedicine Group, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.